Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AURA vs TRDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AURA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–2 Matrix Metrics)

AURA Overall Winner 6-Pillar Tally: AURA 4 – 1 TRDA (1 Tie) Matrix Metrics: AURA 5 – 2 TRDA

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Entrada Therapeutics, Inc. (TRDA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TRDA carries 42.0/100 (HOLD) at $5.06 (N/M Forward P/E, -4256.1% operating margin).

  • Composite vs. Pillar Nuance: While TRDA currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. AURA 31.1/100 SELL), AURA captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4256.1% operating margin) and revenue trajectory (+0.0% vs. -43.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AURA vs TRDA
AURA NASDAQ Head-to-Head Winner
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 8.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.3 · SMA20: $6.66 · SMA50: $6.54
TRDA NASDAQ
Entrada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$5.06
-0.59% 1D
Market Cap $200.8M
TTM Revenue $4.0M
Forward P/E N/M
Beta / 30D Vol 1.66β · 114% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 39.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.7 · SMA20: $4.84 · SMA50: $5.56

6-Pillar Scorecard Institutional Category Breakdown (AURA 4 – 1 TRDA)

Columns: Metric · AURA · TRDA
1. Valuation Multiples TRDA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 50.5x
2. Growth & Scale AURA
Revenue Growth (YoY) +0.0% -43.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.0M
Market Cap $728.6M $200.8M
3. Profitability & Quality AURA
Gross Margin N/A N/A
Operating Margin 0.0% -4256.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -61.7% -59.9%
4. Balance Sheet & Cash Flow AURA
Cash Generation (TTM) -$110M -$166M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $5.43 Book/Sh · -59.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 160.1% (22nd %ile) 317.8% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AURA (5) vs TRDA (2)
Institutional Metric AURA TRDA Criterion Row Edge
Market Capitalization
Scale
$728.6M $200.8M Larger Scale AURA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -43.9% Higher Growth AURA
Operating Margin (TTM)
Profitability
0.0% -4256.1% Higher Margin AURA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-61.7% -59.9% Higher ROE TRDA
52-Week Range Position
Momentum
52% ($5–$10) 8% ($4–$16) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.92β · 75% Vol 1.66β · 114% Vol Lower Realized Risk AURA
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 42.0 / 100 (HOLD) Higher Composite TRDA
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 50.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($26M Net Cash) -$166M EBITDA ($5.43 Book/Sh · -59.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +2.41 pp
AURA: +18.2% · TRDA: +15.79%
3M Horizon AURA +18.76 pp
AURA: -11.64% · TRDA: -30.4%
6M Horizon AURA +10.61 pp
AURA: -3.48% · TRDA: -14.09%
1Y Horizon AURA +72.75 pp
AURA: +30.38% · TRDA: -42.37%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs TRDA. Trailing 12-month operating profitability (AURA 0.0% vs TRDA -4256.1%) and valuation multiples (AURA N/M vs TRDA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M
TRDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.0M
Gross MarginN/A
Op. Margin-4256.1%
ROE / Fwd P/E-59.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TRDA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 317.8%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TRDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TRDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $200.8M market capitalization and -4256.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AURA vs TRDA Key Questions & Quantitative Answers

As of Nov 16, 2026, Aura Biosciences, Inc. (AURA) is the stronger overall head-to-head candidate over Entrada Therapeutics, Inc. (TRDA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TRDA carries 42.0/100 (HOLD) at $5.06 (N/M Forward P/E, -4256.1% operating margin). Composite vs. Pillar Nuance: While TRDA currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. AURA 31.1/100 SELL), AURA captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4256.1% operating margin) and revenue trajectory (+0.0% vs. -43.9% YoY).

AURA leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TRDA at -43.9% YoY revenue growth and +0.0% YoY earnings growth on $4.0M TTM revenue (N/A gross margin, -4256.1% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $4.0M for TRDA. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TRDA.

TRDA screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TRDA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 50.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus TRDA (-59.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, TRDA carries 317.8% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.